Long-term follow-up results from KEYNOTE-041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanoma.
Yokota K, Takenouchi T, Fujisawa Y, Fukushima S, Uchi H, Inozume T, Kiyohara Y, Uhara H, Nakagawa K, Furukawa H, Han S, Watanabe M, Noguchi K, Yamazaki N.
Yokota K, et al. Among authors: furukawa h.
J Dermatol. 2024 May;51(5):632-642. doi: 10.1111/1346-8138.17002. Epub 2024 Mar 26.
J Dermatol. 2024.
PMID: 38529706
Clinical Trial.